Kitano S - Search Results

1

Biomarkers for Immune Checkpoint Inhibitors in Melanoma.

Kitano S, Nakayama T, Yamashita M. Kitano S, et al. Front Oncol. 2018 Jul 18;8:270. doi: 10.3389/fonc.2018.00270. eCollection 2018. Front Oncol. 2018. PMID: 30073150 Free PMC article. Review.

2

Clinical Development of Immune Checkpoint Inhibitors.

Ito A, Kondo S, Tada K, Kitano S. Ito A, et al. Among authors: kitano s. Biomed Res Int. 2015;2015:605478. doi: 10.1155/2015/605478. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161407 Free PMC article. Review.

3

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells.

Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A. Yamashita M, et al. Among authors: kitano s. Sci Rep. 2016 Jan 27;6:19772. doi: 10.1038/srep19772. Sci Rep. 2016. PMID: 26813960 Free PMC article.

4

[Development of immune checkpoint inhibitors].

Kitano S. Kitano S. Rinsho Ketsueki. 2017;58(8):966-976. doi: 10.11406/rinketsu.58.966. Rinsho Ketsueki. 2017. PMID: 28883282 Japanese.

5

[Combination Therapy of Immune Checkpoint Inhibitors].

Kitano S. Kitano S. Gan To Kagaku Ryoho. 2017 Sep;44(9):727-732. Gan To Kagaku Ryoho. 2017. PMID: 28912397 Japanese.

6

Immunotherapy for genitourinary tumors.

Nakayama T, Kitano S. Nakayama T, et al. Among authors: kitano s. Int J Urol. 2019 Mar;26(3):326-333. doi: 10.1111/iju.13902. Epub 2019 Feb 1. Int J Urol. 2019. PMID: 30710374 Review.

7

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors.

Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. Shitara K, et al. Among authors: kitano s. J Immunother Cancer. 2019 Jul 24;7(1):195. doi: 10.1186/s40425-019-0677-y. J Immunother Cancer. 2019. PMID: 31340866 Free PMC article. Clinical Trial.

8

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.

Yoshino K, Nakayama T, Ito A, Sato E, Kitano S. Yoshino K, et al. Among authors: kitano s. BMC Cancer. 2019 Oct 29;19(1):1019. doi: 10.1186/s12885-019-6138-7. BMC Cancer. 2019. PMID: 31664934 Free PMC article.

9

Complete Pathological Response to Neoadjuvant Pembrolizumab in a Patient With Chemoresistant Upper Urinary Tract Urothelial Carcinoma: A Case Report.

Ikarashi D, Kitano S, Ishida K, Nakatsura T, Shimodate H, Tsuyukubo T, Tamura D, Kato R, Sugai T, Obara W. Ikarashi D, et al. Among authors: kitano s. Front Oncol. 2020 Sep 24;10:564714. doi: 10.3389/fonc.2020.564714. eCollection 2020. Front Oncol. 2020. PMID: 33072593 Free PMC article.

10

Transient Depletion of CD4⁺ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer.

Aoki H, Ueha S, Shichino S, Ogiwara H, Shitara K, Shimomura M, Suzuki T, Nakatsura T, Yamashita M, Kitano S, Kuroda S, Wakabayashi M, Kurachi M, Ito S, Doi T, Matsushima K. Aoki H, et al. Among authors: kitano s. Cancer Immunol Res. 2021 Jun;9(6):624-636. doi: 10.1158/2326-6066.CIR-20-0989. Epub 2021 Mar 5. Cancer Immunol Res. 2021. PMID: 33674357 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,189 results

Search Page